Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)
World Journal of Urology · 2026
DOI: 10.1007/s00345-026-06192-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift World Journal of Urology, 2026. Verfasst von Georges Mjaess und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Erasme Hospital and Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB) Brussels, …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Merck.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Neoadjuvant chemo-immunotherapy is emerging as promising strategy in muscle-invasive bladder cancer (MIBC), yet its perioperative safety remains understudied. This post-hoc analysis of the AURA phase-II trial assesses surgical outcomes following neoadjuvant avelumab with or without chemotherapy. METHODS: We analyzed 88 patients with localized MIBC from the phase 2 multicenter AURA trial (NCT03674424) who underwent radical cystectomy after receiving either avelumab monotherapy (n = 22) or chemo-immunotherapy (n = 66). Surgical complications were classified using Clavien-Dindo criteria. A LASSO regression was used to identify predictors of overall complications, followed by multivariable and mixed-effects models. RESULTS: No increased intra-operative surgical complexity was noted. The overall complication rate was 52%. Major complications occurred significantly more often in the chemo-immunotherapy group compared to monotherapy (21.2% vs. 15.4%, p = 0.03), despite more favorable patient profiles. Neobladder diversion and open surgery were both associated with higher complication rates (81% vs. ileal conduit 40%, p = 0.001; 61% vs. robotic surgery 53%, p = 0.04, respectively). Uretero-enteric stricture occurred in 7.6% of patients, with no significant difference between groups. The predictive model demonstrated high accuracy (AUC 0.851) and identified key risk factors for major complications: neobladder reconstruction (OR 10.9[2.4-48.4], p = 0.002), older age, longer operative time, and low preoperative hemoglobin. Limitations include the non-randomized treatment allocation and small sample size in the monotherapy group, which may limit generalizability. CONCLUSION: Radical cystectomy after neoadjuvant immunotherapy+/-chemotherapy is feasible, safe, and is not associated with increased intra-operative surgical complexity. Neoadjuvant chemo-immunotherapy prior to cystectomy was associated with increased risk of major surgical complications compared to immunotherapy alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Erasme Hospital and Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB) Brussels, Route de Lennik 808, 1070, Brussels, Belgium.
- Department of Urology, Claude Huriez Hospital, Centre Hospitalier Universitaire De Lille, Lille, France.
- Department of Urology, Nouvel Hôpital Civil-Hôpitaux Universitaires De Strasbourg, Strasbourg, France.
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020- U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
- Department of Medical Oncology, Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
- Department of Medical Oncology, ICANS, Strasbourg, France.
Förderung
- Merck
Zitieren
APA
Mjaess, G., Quackels, T., Fantoni, J. C., Tricard, T., Marcq, G., Blanc, J., Barthelemy, P., Carnot, A., Sideris, S., Awada, A., Chanza, N. M., Peltier, A., Albisinni, S., Diamand, R., & Roumeguère, T. (2026). Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004). World Journal of Urology. https://doi.org/10.1007/s00345-026-06192-9
Vancouver
Mjaess G, Quackels T, Fantoni JC, Tricard T, Marcq G, Blanc J, et al. Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004). World Journal of Urology. 2026. doi:10.1007/s00345-026-06192-9
BibTeX
@article{Mjaess2026,
author = {Mjaess, Georges and Quackels, Thierry and Fantoni, Jean-Christophe and Tricard, Thibault and Marcq, Gautier and Blanc, Jérémy and Barthelemy, Philippe and Carnot, Aurélien and Sideris, Spyridon and Awada, Ahmad and Chanza, Nieves Martinez and Peltier, Alexandre and Albisinni, Simone and Diamand, Romain and Roumeguère, Thierry},
title = {Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)},
journal = {World Journal of Urology},
year = {2026},
doi = {10.1007/s00345-026-06192-9}
}
EUVIMED